Journal article

A >= 1 log rise in RQ-PCR transcript levels defines molecular relapse in core binding factor acute myeloid leukemia and predicts subsequent morphologic relapse

Steven Lane, Russell Saal, Peter Mollee, Mark Jones, Andrew Grigg, Kerry Taylor, John Seymour, Glen Kennedy, Bronwyn Williams, Karen Grimmett, Vanessa Griffiths, Devinder Gill, Matthew Hourigan, Paula Marlton

LEUKEMIA & LYMPHOMA | TAYLOR & FRANCIS LTD | Published : 2008

Abstract

Core binding factor acute myeloid leukemia (CBF AML), with t(8;21)(q22;q22), inv(16)(p13q22) or t(16;16)(p13;q22) and the associated fusion gene transcripts AML1/ETO or CBFbeta/MYH11, has a favourable clinical prognosis although significant numbers of patients still suffer relapse. We examined the prognostic utility of serial bone marrow minimal residual disease (MRD) monitoring by RQ-PCR in a cohort of patients with CBF AML with long term clinical follow-up. Twenty-nine patients were evaluated with a median follow of 34 months. Twelve relapses occurred at a median of 11 months (range 4 - 17) from diagnosis. RQ-PCR levels at diagnosis, post-induction chemotherapy and post-consolidation were ..

View full abstract